Benitec Biopharma Inc. (NASDAQ:BNTC) Director Suvretta Capital Management, L Acquires 27,502 Shares

Benitec Biopharma Inc. (NASDAQ:BNTC) Director Suvretta Capital Management, L purchased 27,502 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were acquired at an average price of $10.98 per share, for a total transaction of $301,971.96. Following the completion of the acquisition, the director now directly owns 7,981,725 shares in the company, valued at approximately $87,639,340.50. This represents a 0.35 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Suvretta Capital Management, L also recently made the following trade(s):

• On Tuesday, December 3rd, Suvretta Capital Management, L acquired 42,000 shares of Benitec Biopharma stock. The stock was bought at an average cost of $9.60 per share, with a total value of $403,200.00.

Benitec Biopharma Price Performance

BNTC stock traded up $0.42 during midday trading on Thursday, hitting $12.00. 30,035 shares of the stock traded hands, compared to its average volume of 48,807. Benitec Biopharma Inc. has a 1-year low of $2.69 and a 1-year high of $13.29. The firm has a market cap of $278.59 million, a P/E ratio of -4.23 and a beta of 0.89. The stock’s fifty day simple moving average is $10.88 and its 200-day simple moving average is $9.52.

Analyst Ratings Changes

BNTC has been the subject of a number of recent analyst reports. Piper Sandler restated an “overweight” rating on shares of Benitec Biopharma in a research note on Friday, October 18th. Oppenheimer assumed coverage on Benitec Biopharma in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $35.00 target price on the stock. Guggenheim restated a “buy” rating and set a $17.00 price target on shares of Benitec Biopharma in a research report on Tuesday, December 3rd. Robert W. Baird assumed coverage on shares of Benitec Biopharma in a report on Friday, December 13th. They issued an “outperform” rating and a $30.00 price target on the stock. Finally, Baird R W raised shares of Benitec Biopharma to a “strong-buy” rating in a research report on Thursday, December 12th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Benitec Biopharma presently has an average rating of “Buy” and a consensus target price of $24.43.

Institutional Investors Weigh In On Benitec Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BNTC. GAMMA Investing LLC grew its stake in Benitec Biopharma by 20.3% during the 3rd quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 1,102 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Benitec Biopharma by 31.3% during the third quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock worth $772,000 after acquiring an additional 20,012 shares during the period. Acuta Capital Partners LLC purchased a new position in shares of Benitec Biopharma in the 3rd quarter valued at about $274,000. Simplify Asset Management Inc. acquired a new stake in Benitec Biopharma in the second quarter valued at $358,000. Finally, Nantahala Capital Management LLC purchased a new stake in Benitec Biopharma in the 2nd quarter valued at approximately $5,881,000. Hedge funds and other institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.